Biocompatibility and proteomic profiling of DMSA-coated iron nanocubes in a human glioblastoma cell line-Reference-Cited by-同舟云学术

Biocompatibility and proteomic profiling of DMSA-coated iron nanocubes in a human glioblastoma cell line

Published:2024-01-25 Issue: Volume: Page:
ISSN:1743-5889
Container-title:Nanomedicine
language:en
Short-container-title:Nanomedicine

Author:

Ulanova Marina¹^ORCID,Gloag Lucy²^ORCID,Kim Chul-Kyu¹,Bongers Andre³⁴⁵^ORCID,Kim Duong Hong Thien⁶,Gooding J Justin⁶⁷^ORCID,Tilley Richard D³⁶⁷^ORCID,Sachdev Perminder S¹⁸^ORCID,Braidy Nady¹^ORCID

Affiliation:

1. Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales, Sydney, New South Wales, 2052, Australia

2. School of Mathematical & Physical Science, Faculty of Science, University of Technology Sydney, Sydney, New South Wales, 2007, Australia

3. Mark Wainwright Analytical Centre, University of New South Wales, Sydney, New South Wales, 2052, Australia

4. Prince of Wales Clinical School, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, 2052, Australia

5. National Imaging Facility, University of Queensland, St Lucia, Queensland, 4072

6. School of Chemistry, University of New South Wales, Sydney, New South Wales, 2052, Australia

7. Australian Centre for NanoMedicine, University of New South Wales, Sydney, New South Wales, 2052, Australia

8. Neuropsychiatric Institute, Euroa Centre, Prince of Wales Hospital, Sydney, New South Wales, 2031, Australia

Abstract

Background: Superparamagnetic iron core iron oxide shell nanocubes have previously shown superior performance in magnetic resonance imaging T2 contrast enhancement compared with spherical nanoparticles. Methods: Iron core iron oxide shell nanocubes were synthesized, stabilized with dimercaptosuccinic acid (DMSA-NC) and physicochemically characterized. Magnetic resonance imaging (MRI) contrast enhancement and biocompatibility were assessed in vitro. Results: DMSA-NC showed a transverse relaxivity of 122.59 mM-1·s-1 Fe. Treatment with DMSA-NC did not induce cytotoxicity or oxidative stress in U-251 cells, and electron microscopy demonstrated DMSA-NC localization within endosomes and lysosomes in cells following internalization. Global proteomics revealed dysregulation of iron storage, transport, transcription and mRNA processing proteins. Conclusion: DMSA-NC is a promising T2 MRI contrast agent which, in this preliminary investigation, demonstrates favorable biocompatibility with an astrocyte cell model.

Funder

Australian Research Council Discovery Early Career Award

Australian Research Council Discovery Project

National Health and Medical Research Council Investigator Grant

Publisher

Future Medicine Ltd

Subject

Development,General Materials Science,Biomedical Engineering,Medicine (miscellaneous),Bioengineering

Link

https://www.futuremedicine.com/doi/pdf/10.2217/nnm-2023-0304

Reference86 articles.

1. Surface-engineered prussian blue nanozymes as artificial receptors for universal pattern recognition of metal ions and proteins

2. Current Advances of Atomically Dispersed Metal-Centered Nanozymes for Tumor Diagnosis and Therapy

3. Development of a new vesicular formulation for delivery of Ifosfamide: Evidence from in vitro, in vivo, and in silico experiments

4. Stability of polyelectrolyte-coated iron nanoparticles for T 2 -weighted magnetic resonance imaging

5. Simple Synthesis and Functionalization of Iron Nanoparticles for Magnetic Resonance Imaging